Dark Streaming/Mobile Old Site Home Daily Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:27:13 EDT Thu 30 Mar 2023
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:INCY - INCYTE CORPORATION - http://www.incyte.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
INCY - Q71.04-0.10-0.1912.664,25510,46871.39  71.48  70.8484.86  65.0716:13:53Mar 2715 min RT 2¢

Recent Trades - Last 10 of 10468
Time ETExPriceChangeVolume
16:13:53Q71.0978-0.042245,370
16:10:03Q71.04-0.1016,546
16:06:24Q69.55-1.591
16:03:48Q69.5515-1.58851
16:02:23Q71.04-0.1066
16:02:22Q71.04-0.10323
16:02:22Q71.04-0.10686
16:02:20Q71.04-0.10197
16:02:17Q71.04-0.10108
16:02:13Q71.04-0.106,546

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2023-03-27 02:00U:INCYNews ReleaseIncyte Announces Japanese Approval of Pemazyre ‚ ® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
2023-03-23 20:55U:INCYNews ReleaseIncyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
2023-03-22 13:14U:INCYNews ReleaseIncyte Announces FDA Approval of Zynyz ¢ „ ¢ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
2023-03-18 15:40U:INCYNews ReleaseIncyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
2023-03-18 10:40U:INCYNews ReleaseIncyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura ‚ ® (Ruxolitinib) Cream in Vitiligo
2023-03-14 18:30U:INCYNews ReleaseIncyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
2023-03-07 06:30U:INCYNews ReleaseCaris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline
2023-03-06 12:23U:INCYNews ReleaseMultiple Abstracts from Incyte ¢ € ™s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
2023-03-03 16:35U:INCYNews ReleaseIncyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis